Boehringer buys PhII respiratory drug program

Boehringer Ingelheim is beefing up its pipeline of respiratory drugs. The pharma company has snagged global rights to FX125L, a small molecule in mid-stage development for inflammatory diseases from the U.K.'s Funxional Therapeutics. No terms were discussed. "Boehringer Ingelheim is delighted to add another promising compound to its development pipeline of drugs for the treatment of respiratory disease, one of its most important therapeutic areas", said Prof. Klaus Dugi, the corporate SVP. "By acquiring the Funxional Therapeutics program, we are looking forward to bringing a potential new therapy to patients, for instance those suffering from Asthma and COPD." Release